Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether antiplatelet agent changes major bleeding (not reported) compared with placebo (very low certainty).
Antiplatelet agent showed no clear difference in progression of carotid stenosis (DUS/every 6 months) compared with placebo (low certainty).
Antiplatelet agent showed no clear difference in adverse events (not reported) compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical worsening: need for invasive mechanical ventilation, or… compared with placebo or standard care alone (high certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard care alone (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Convalescent plasma showed no clear difference in time to symptom resolution (absolute effect calculated for day 12) compared with placebo or standard care alone (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events compared with placebo or standard care alone (low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical improvement: participants discharged from hospital compared with placebo or standard care alone (high certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
Vedolizumab leads to higher induction of clinical remission (6–10 weeks) compared with placebo (high certainty).
Vedolizumab leads to higher induction of clinical response (6–10 weeks) compared with placebo (high certainty).